What would you like first: the good news or the bad news? Let me start with the bad. Life expectancy among patients in the U.S. with thyroid cancer lags behind that in Korea. In fact, the vast majority of patients diagnosed with thyroid cancer in Korea are cured of that illness, a statement I can’t…
It is well accepted among health economics wonks that the lion’s share of pharmaceutical company profits come when these companies hold exclusive rights to their products. Once their blockbuster pills go “generic,” competitors enter the marketplace and profits plummet. Consider captopril, a groundbreaking heart failure medication introduced in the early 80s by Bristol-Myers Squibb under…
In June of 2013, the American Medical Association officially recognized obesity as a disease. The organization had its reasons. For starters, obesity leads to heart attacks, strokes, diabetes, early-onset degenerative arthritis…and just about every other illness on the planet. In addition, people with obesity face a very difficult time overcoming their condition: Short of highly…
Here is a podcast I participated in, put out by folks at GWU. A quickish interview on the challenge of getting doctors to stop doing things they ought to stop doing. You can also listen to it on iTunes, or on Stitcher.
In the old days, blockbuster drugs were moderately expensive pills taken by hundreds of thousands of patients. Think blood pressure, cholesterol and diabetes pills. But today, many blockbusters are designed to target much less common diseases, illnesses like multiple sclerosis and rheumatoid arthritis or even specific subcategories of cancer. These medications have become blockbusters not…
In a few months, we will find out whether the Supreme Court has decided that a critical part of the Affordable Care Act is unconstitutional. If that happens, lots of people will be in lots of trouble, financially speaking. Here is a wonderful article in a North Carolina newspaper laying out some of the issues…
The Managing Editor of the New England Journal of Medicine interviewed me about the piece I wrote, with David Comerford and Eric Johnson, on redesigning the health insurance exchanges. For those of you with long commutes, here is that podcast: Healthcare.gov 3.0
Here is a nice follow-up story on my recent New England Journal article on improving the design of health insurance exchanges. Comparing health insurance plans – whether signing up through Healthcare.gov or weighing employer-sponsored plans with a spouse – can feel like wading through a sea of information on deductibles, co-payments and monthly premiums. Now…
I joined two other, much smarter, colleagues in calling for the use of behavioral economics and decision psychology to improve the design of the websites people use to purchase health insurance in the U.S. That article came out today in the New England Journal of Medicine. Here is a taste: In October 2013, the Affordable…
Cholesterol pills are one of the great medical advances I’ve witnessed during my professional career. I am talking specifically about a category of medications called statins, drugs like Lipitor and Pravachol. These drugs have prevented probably hundreds of thousands of heart attacks and strokes. Only one problem with these drugs, however: statins won’t help people…